Torthaí cuardaigh - Dylan Conklin

  • 1 - 9 toradh as 9 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

    PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro de réir Richard S. Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J. Cohen, Amrita J. Desai, Charles Ginther, Mohammad Atefi, Isan Chen, Camilla Fowst, Gerret Los, Dennis J. Slamon

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer

    Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer de réir Zev A. Wainberg, Adrian Anghel, Amy M. Rogers, Amrita J. Desai, Ondrej Kalous, Dylan Conklin, Raul Ayala, Neil A. O’Brien, Cornelia Quadt, Mikhail Akimov, Dennis J. Slamon, Richard S. Finn

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

    Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib de réir Ondrej Kalous, Dylan Conklin, Amrita J. Desai, Neil A. O’Brien, Charles Ginther, Lee Anderson, David J. Cohen, Carolyn D. Britten, Ian W. Taylor, James G. Christensen, Dennis J. Slamon, Richard S. Finn

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

    Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT de réir Neil A. O’Brien, K McDonald, Tong Luo, Erika von Euw, Ondrej Kalous, Dylan Conklin, Sara A. Hurvitz, Emmanuelle di Tomaso, Christian Schnell, Ronald Linnartz, Richard S. Finn, Samit Hirawat, Dennis J. Slamon

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

    Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer de réir Neil A. O’Brien, Dylan Conklin, Richard P. Beckmann, Tong Luo, Kevin Chau, Josh D. Thomas, Ann Mc Nulty, Christophe C. Marchal, Ondrej Kalous, Erika von Euw, Sara A. Hurvitz, Colleen Mockbee, Dennis J. Slamon

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

    Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer de réir Neil A. O’Brien, Martina S.J. McDermott, Dylan Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Alex Gaither, Sara A. Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat, Dennis J. Slamon

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines

    Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines de réir Eniko Papp, Dorothy Hallberg, Gottfried E. Konecny, Daniel C. Bruhm, Vilmos Adleff, Michaël Noë, Ioannis Kagiampakis, Doreen N. Palsgrove, Dylan Conklin, Yasuto Kinose, James R. White, Michael F. Press, Ronny Drapkin, Hariharan Easwaran, Stephen B. Baylin, Dennis J. Slamon, Victor E. Velculescu, Robert B. Scharpf

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Concise total syntheses of (–)-jorunnamycin A and (–)-jorumycin enabled by asymmetric catalysis

    Concise total syntheses of (–)-jorunnamycin A and (–)-jorumycin enabled by asymmetric catalysis de réir Eric R. Welin, Aurapat Ngamnithiporn, Max Klatte, Guillaume Lapointe, Gerit Pototschnig, Martina S.J. McDermott, Dylan Conklin, Christopher D. Gilmore, Pamela M. Tadross, Christopher K. Haley, Kenji Negoro, Emil Glibstrup, Christian U. Grünanger, Kevin M. Allan, Scott C. Virgil, Dennis J. Slamon, Brian M. Stoltz

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays

    Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays de réir Jun Li, Wei Zhao, Rehan Akbani, Wenbin Liu, Zhenlin Ju, Shiyun Ling, Christopher P. Vellano, Paul Roebuck, Qinghua Yu, Agda Karina Eterovic, Lauren A. Byers, Michael A. Davies, Wanleng Deng, Y.N. Vashisht Gopal, Guo Chen, Erika M. von Euw, Dennis J. Slamon, Dylan Conklin, John V. Heymach, Adi F. Gazdar, John D. Minna, Jeffrey N. Myers, Yiling Lu, Gordon B. Mills, Han Liang

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: